A Pharmacodynamic Comparison of Prasugrel (LY640315) Versus High Dose Clopidogrel in Subjects With Type 2 Diabetes Mellitus and Coronary Artery Disease.

Trial Profile

A Pharmacodynamic Comparison of Prasugrel (LY640315) Versus High Dose Clopidogrel in Subjects With Type 2 Diabetes Mellitus and Coronary Artery Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Clopidogrel; Prasugrel
  • Indications Coronary artery disease; Embolism and thrombosis; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms OPTIMUS-3
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 30 Aug 2010 Results have been presented at ESC Congress 2010: Annual Congress of the European Society of Cardiology.
    • 16 Nov 2009 Results presented at the 82nd Annual Scientific Sessions of the American Heart Association (AHA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top